Took the Wrong Tirzepatide Dose? What to Do Next

An extra tirzepatide injection, wrong-strength pen or uncertain vial measurement deserves prompt professional advice. Do not wait for severe symptoms to decide whether the dose was a problem. The Zepbound label directs people with an overdose to contact the U.S. Poison Help Line at 1-800-222-1222 or a medical toxicologist for management recommendations.¹

If someone collapses, has a seizure, cannot be awakened or has trouble breathing, seek emergency help immediately. A general article cannot determine whether your particular exposure can be watched at home.

Get the facts together

Have the medication packaging, prescription directions and injection device available. Tell the professional what you were meant to take, what you think you actually took and when. Include any previous injection in the same week and the names of other diabetes medicines you use.

For a vial, read the concentration exactly as printed. State the amount drawn into the syringe and the syringe type instead of translating everything into “units” from memory. For a pen, read the strength from the device and describe what happened. These are different error scenarios and may require different follow-up.

Do not make a second correction on your own

Do not take another injection to correct uncertainty about an incomplete dose, and do not schedule a compensating dose yourself. A clinician or pharmacist needs to resolve the amount already administered before deciding the next step. The weekly schedule is explained in our dosage guide, but the schedule is not an overdose-management plan.

The label’s ordinary missed-dose rule applies to a missed injection. It does not tell you how to manage an extra injection or a mistake involving several strengths. Those questions should go directly to your care team.¹

Why symptoms may need continued follow-up

Tirzepatide is long acting. The label notes that a period of observation and treatment may be necessary after an overdose because of its approximately five-day half-life. Being comfortable shortly after an injection does not automatically mean no follow-up is needed.¹

Ask the professional what symptoms to monitor, when to call back and how to handle the next scheduled dose. Report repeated vomiting, inability to keep fluids down, severe abdominal pain, fainting or symptoms of low blood sugar. Our hypoglycemia guide explains why insulin and sulfonylureas are particularly relevant to that conversation.

Vial errors need a concentration check

FDA has received reports of problems involving compounded GLP-1 dosing, including administration errors and doses beyond approved-label schedules. A change in concentration can make a familiar syringe marking represent a different drug amount.²

Ask the dispensing pharmacy to show your prescribed dose in milligrams, the concentration in milligrams per milliliter, and the volume to draw up on your specific syringe. Do this again when the formulation, concentration or supplies change. Our milligrams and units guide explains the distinction without substituting for the prescription.

Before treatment resumes

Keep a written record of the advice you received and the agreed next injection date and strength. If several people help with your medication, identify who records each dose so a second person does not unknowingly repeat it. When an error involves confusing packaging or instructions, ask the pharmacy to review how the next refill will be labeled.

The goal is to resolve this exposure safely and remove the cause of the mistake. Do not rely on another patient’s experience with an apparently similar dose.